Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel drug discovery platform for spinocerebellar ataxia, using fluorescence technology targeting β-III-spectrin.

The Journal of biological chemistry - 1 Jan 2000

Rebbeck Robyn T, Andrick Anna K, Denha Sarah A, Svensson Bengt, Guhathakurta Piyali, Thomas David D, Hays Thomas S, Avery Adam W

Abstract excerpt

Numerous diseases are linked to mutations in the actin-binding domains (ABDs) of conserved cytoskeletal proteins, including β-III-spectrin, α-actinin, filamin, and dystrophin. A β-III-spectrin ABD mutation (L253P) linked to spinocerebellar ataxia type 5 (SCA5) causes a dramatic increase in actin binding. Reducing actin binding of L253P is thus a potential therapeutic approach for SCA5 pathogenesis. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fluorescence Resonance Energy Transfer
Share to Marine Toxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neuroprotective Agents

Share to Protein Conformation, alpha-Helical

Share to Protein Conformation, beta-Strand

Share to Red Fluorescent Protein

Share to Spectrin

Share to Spinocerebellar Ataxias

Source

Open in PubMed Open full text

Identifiers

PMID: 33839680
DOI: 10.1074/jbc.RA120.015417
PMCID: PMC7948455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel drug discovery platform for spinocerebellar ataxia, using fluorescence technology targeting β-III-spectrin.PMID 33839680Read ↗

Increased actin binding is a shared molecular consequence of numerous spinocerebellar ataxia mutations in β-III-spectrinSemantic proximity Read ↗

A human β-III-spectrin spinocerebellar ataxia type 5 mutation causes high-affinity F-actin binding.Semantic proximity Read ↗

Increased Actin Binding Is a Shared Molecular Consequence of Numerous SCA5 Mutations in β-III-Spectrin.Semantic proximity Read ↗

Molecular consequences of SCA5 mutations in the spectrin-repeat domains of β-III-spectrin.Semantic proximity Read ↗

β-III-spectrin N-terminus is required for high-affinity actin binding and SCA5 neurotoxicity.Semantic proximity Read ↗

Discovery of Small Molecule Inhibitors of Huntingtin Exon 1 Aggregation by FRET-Based High-Throughput Screening in Living Cells.Semantic proximity Read ↗

Spinocerebellar ataxia type 5.Semantic proximity Read ↗

β-III-spectrin spinocerebellar ataxia type 5 mutation reveals a dominant cytoskeletal mechanism that underlies dendritic arborization.Semantic proximity Read ↗

Phenotypic Screening for Friedreich Ataxia Using Random shRNA Selection.Semantic proximity Read ↗

A small molecule high throughput screening platform to profile conformational properties of nascent, ribosome-bound proteins.Semantic proximity Read ↗

β-III spectrin underpins ankyrin R function in Purkinje cell dendritic trees: protein complex critical for sodium channel activity is impaired by SCA5-associated mutations.Semantic proximity Read ↗

High-Throughput Screening for Drugs that Modulate Intermediate Filament Proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.